Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this prospective study, ritlecitinib effectively reduced hair loss in patients with severe alopecia areata, with 43.3% of participants achieving a 20 or lower SALT score by week 24, and showed a good midterm safety profile.

This study found that Israeli patients with alopecia areata had a higher prevalence of comorbid conditions, including food allergies and chronic spontaneous urticaria, compared to matched controls.

This case report highlights two instances of alopecia areata, demonstrating diverse presentations, and suggests upadacitinib as a promising treatment option, resulting in hair regrowth within 3–6 months, without worsening sarcoidosis-related skin lesions.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

This consensus from the Taiwanese Dermatological Association suggests that for mild to moderate alopecia areata, first-line treatments may include topical or intralesional corticosteroids, possibly with topical minoxidil, while severe cases might require systemic corticosteroids or Janus kinase inhibitors.

This study reports that yellow dots in a higher number per field of vision were the most consistent dermoscopic finding in severe cases of alopecia areata.

In this retrospective study, baricitinib effectively improved alopecia areata in 78.7% of patients by the end of treatment, with significant hair regrowth observed, particularly in those with disease duration of four years or less, and showed no serious adverse events.

In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.

This review highlights the traditional use and potential therapeutic activities of Asiasari Radix in drug discovery, but it reports no new clinical results.

Organizations help patients access discounts for expensive dermatology medications.

This study reported that etrasimod did not achieve significant improvements in hair regrowth for moderate to severe alopecia areata at 24 weeks, although it showed a dose-dependent trend and was safe and well-tolerated over 52 weeks.

In this retrospective study of alopecia areata patients across several European countries, researchers observed a notable reduction in SALT scores, but few patients reached or maintained a clinically significant SALT score of ≤20, indicating potentially limited effectiveness of current treatments for extensive hair loss.

This study found that early treatment of alopecia areata with JAK inhibitors can improve patients' physical and psychological quality of life without worsening skin lesions associated with sarcoidosis.

This Italian study observed that one third of patients with 25 to 50% scalp hair loss from alopecia areata still experienced active patchy disease at long-term follow-up, and another third progressed to more severe forms like alopecia totalis or universalis, with limited recovery.

In an outpatient cardiology center, this study found that introducing the AHA/ACC ABI screening protocol significantly increased the frequency of ABI ordering by 31.6% for symptomatic patients.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

This study found that upadacitinib significantly improved hair regrowth compared to placebo in adults and adolescents with severe alopecia areata, and demonstrated a positive benefit-risk profile.

In this study at Tohoku University Hospital, 41% of severe alopecia areata patients achieved significant hair regrowth with baricitinib treatment over 9 months, with predictors of better outcomes including shorter disease duration, female sex, initial mild disease, certain alopecia types, and prior IVMP therapy.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

In this study, increasing cases of allergic contact dermatitis in Bulgaria were linked to the use of natural products like propolis and marigold.

In this study, researchers identified yellow dots as the most common dermoscopic feature of alopecia areata, followed by black dots, broken hairs, short vellus hair, and tapering hairs.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

This study is collecting real-world data to evaluate abrocitinib and conventional systemic treatments in moderate-to-severe atopic dermatitis across five European registers over a three-year period.

JAK inhibitors are generally safe for treating alopecia areata.

The BEARD Score helps assess beard hair loss in alopecia areata for better treatment.

This review discusses current and emerging treatments for alopecia areata, emphasizing systemic treatments for moderate to severe cases, and reports no new clinical results.